About: Health-economic aspects of cystic fibrosis screening and therapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Health-economic aspects of cystic fibrosis screening and therapy Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://dx.doi.org/10.1183/1025448x.10010613
Description	There is an increasing need to manage cost-effectiveness issues of novel or relatively expensive technologies that are currently in use or being proposed for the treatment of cystic fibrosis (CF) (e.g. cystic fibrosis transmembrane conductance regulator (CFTR) modulation therapy). Health-economic evaluations of rising pharmacotherapeutic costs, as the major driver of overall cost, have to be part of the cost analysis of chronic and progressive (rare) diseases like CF that may require lifelong therapy. Total costs include not only direct healthcare costs but also the cost of lost productivity by both patients and family caregivers. When considering the results of cost-effectiveness analysis of new technologies associated with the management of CF, it is unreasonable to expect that the incremental cost-effectiveness ratio to be less than the generally applied thresholds (willingness to pay) for other common diseases. Therefore, when assessing CF and other rare diseases, such analyses should include complex health technology assessment approaches, which evaluate comparative treatment effectiveness (novel and established), as well as wider social benefits and ethical aspects. There is an increasing need to manage cost-effectiveness issues of novel or relatively expensive technologies that are currently in use or being proposed for the treatment of cystic fibrosis (CF) (e.g. cystic fibrosis transmembrane conductance regulator (CFTR) modulation therapy). Health-economic evaluations of rising pharmacotherapeutic costs, as the major driver of overall cost, have to be part of the cost analysis of chronic and progressive (rare) diseases like CF that may require lifelong therapy. Total costs include not only direct healthcare costs but also the cost of lost productivity by both patients and family caregivers. When considering the results of cost-effectiveness analysis of new technologies associated with the management of CF, it is unreasonable to expect that the incremental cost-effectiveness ratio to be less than the generally applied thresholds (willingness to pay) for other common diseases. Therefore, when assessing CF and other rare diseases, such analyses should include complex health technology assessment approaches, which evaluate comparative treatment effectiveness (novel and established), as well as wider social benefits and ethical aspects. (en)
Title	Health-economic aspects of cystic fibrosis screening and therapy Health-economic aspects of cystic fibrosis screening and therapy (en)
skos:prefLabel	Health-economic aspects of cystic fibrosis screening and therapy Health-economic aspects of cystic fibrosis screening and therapy (en)
skos:notation	RIV/00216208:11130/14:10293404!RIV15-MSM-11130___
http://linked.open...avai/riv/aktivita	I
http://linked.open...avai/riv/aktivity	I
http://linked.open...vai/riv/dodaniDat	2015
http://linked.open...aciTvurceVysledku	Turnovec, Marek Macek jr., Milan Kubáčková, Kateřina Doležal, Tomáš
http://linked.open.../riv/druhVysledku	C - Kapitola v knize
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Karlova v Praze / 2. lékařská fakulta
http://linked.open...dnocenehoVysledku	18844
http://linked.open...ai/riv/idVysledku	RIV/00216208:11130/14:10293404
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	orphan drug; ivacaftor; cystic fibrosis transmembrane conductance regulator (en)
http://linked.open.../riv/klicoveSlovo	cystic fibrosis transmembrane conductance regulator ivacaftor orphan drug
http://linked.open...ontrolniKodProRIV	[2FD9865DB7A9]
http://linked.open...i/riv/mistoVydani	Sheffield
http://linked.open...vEdiceCisloSvazku	ERS Monograph
http://linked.open...i/riv/nazevZdroje	Cystic Fibrosis
http://linked.open...in/vavai/riv/obor	EB
http://linked.open...ichTvurcuVysledku	4 (xsd:int)
http://linked.open...v/pocetStranKnihy	319 (xsd:int)
http://linked.open...cetTvurcuVysledku	5 (xsd:int)
http://linked.open...UplatneniVysledku	2014
http://linked.open...iv/tvurceVysledku	Klimeš, Jiří Doležal, Tomáš Macek, Milan Kubáčková, Kateřina Turnovec, Marek
number of pages	16 (xsd:int)
http://bibframe.org/vocab/doi	10.1183/1025448x.10010613
http://purl.org/ne...btex#hasPublisher	European Respiratory Society
https://schema.org/isbn	978-1-84984-051-4
http://localhost/t...ganizacniJednotka	11130

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 67 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software